<DOC>
	<DOCNO>NCT00571610</DOCNO>
	<brief_summary>Reduction mitral regurgitation due safe placement PTMA device coronary sinus .</brief_summary>
	<brief_title>Montreal Safety Efficacy Percutaneous Transvenous Mitral Annuloplasty Device</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Functional MR 2+ 4+ leave ventricular enlargement Symptomatic heart failure 20 % 50 % LVEF mitral regurgitation organic origins recent cardiac intervention severe comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Mitral Regurgitation</keyword>
</DOC>